Respiratory – Medxy AI

Impact of the 2023 Safety Net Policy on Kidney After Lung Transplantation: Early Changes in Transplant Practices and Outcomes

By MedXY 09/22/2026

Following the 2023 US safety net policy for kidney after lung transplantation, a shift from simultaneous lung-kidney transplants to early kidney transplantation post lung transplant was observed, with improved short-term outcomes and reduced delisting rates.

Allergy & Immunology news Respiratory

Dupilumab’s Impact on Mucus Plug Dynamics and Radiodensity in Moderate to Severe Asthma: A CT Imaging Perspective

By MedXY 09/22/2026

Dupilumab treatment in moderate to severe asthma significantly reduces mucus plug burden, resolves existing plugs, limits new plug formation, and decreases plug radiodensity on CT scans, correlating with improved lung function and ventilation.

Infectious Diseases news Respiratory

East Asia-Specific Mycobacterium massiliense ST120: Phylogenomics, Clinical Impact, and Challenges in Pulmonary Disease Management

By MedXY 09/20/2026

The ST120 strain of Mycobacterium massiliense, prevalent in East Asia, exhibits unique genetic features linked to increased virulence and worse treatment outcomes in pulmonary disease.

Critical Care news Respiratory

Distinct Weaning Phenotypes in Invasive Mechanical Ventilation Failures: Insights from the WEAN SAFE Cohort

By MedXY 09/20/2026

This study identifies three distinct phenotypes among patients failing to wean from invasive mechanical ventilation, linking failed initial attempts, withdrawal decisions, and mortality, highlighting the need for tailored management strategies in critical care.

Cardiology news Respiratory

Brain Natriuretic Peptide Levels as a Prognostic Biomarker After Pulmonary Endarterectomy in Chronic Thromboembolic Pulmonary Hypertension

By MedXY 09/20/2026

This study demonstrates that elevated brain natriuretic peptide (BNP) post-pulmonary endarterectomy strongly predicts mortality in chronic thromboembolic pulmonary hypertension (CTEPH), providing valuable prognostic information beyond persistent pulmonary hypertension status.

news Respiratory

Evaluating High Intensity Interval Training Versus Moderate Intensity Continuous Training in Fibrotic Interstitial Lung Disease: Insights from a Randomized Controlled Trial

By MedXY 09/20/2026

A randomized trial compared high intensity interval training (HIIT) with standard moderate intensity continuous training (MICT) in fibrotic interstitial lung disease, finding no superiority of HIIT but confirming its safety and feasibility.

Diabetes & Endocrinology news Respiratory

GLP-1 Receptor Agonists and the Prevention of Obstructive Sleep Apnea in Type 2 Diabetes: Insights from a Large UK Cohort Study

By MedXY 09/20/2026

A comprehensive UK cohort study shows that GLP-1 receptor agonists do not reduce the incidence of obstructive sleep apnea compared to DPP-4 inhibitors in obese patients with type 2 diabetes.

Allergy & Immunology news Respiratory

Rademikibart and Eosinophil Counts in Moderate-to-Severe Asthma: Insights from a Phase 2b Randomized Trial

By MedXY 09/18/2026

This article reviews exploratory analyses from a phase 2b trial examining eosinophil count changes in adults with uncontrolled moderate-to-severe asthma treated with the IL-4Rα inhibitor rademikibart, indicating a low risk of treatment-emergent hypereosinophilia.

Infectious Diseases news Respiratory

Decoding Pseudomonas aeruginosa Subtypes: Implications for Clinical Variability in Bronchiectasis

By MedXY 09/18/2026

Distinct Pseudomonas aeruginosa abundance and interaction patterns in bronchiectasis patients reveal heterogeneity influencing clinical outcomes and treatment responses, offering new avenues for personalized management.

news Pediatrics Respiratory

Decoding Persistent Tachypnea of Infancy: Genetic Insights Expand Diagnostic Paradigms

By MedXY 09/17/2026

Comprehensive exome sequencing reveals genetic heterogeneity in persistent tachypnea of infancy (PTI/NEHI), highlighting its phenotype nature and association with neurodevelopmental disorders, advocating early genetic testing to enhance diagnosis.

Critical Care news Respiratory

Mechanical Ventilation-Induced Neutrophil Extracellular Vesicles: A Novel Mediator in Postoperative Pulmonary Complications

By MedXY 09/17/2026

Mechanical ventilation during surgery induces neutrophil extracellular vesicles that propagate lung inflammation and contribute to postoperative pulmonary complications, highlighting potential new biomarkers and therapeutic targets.

Infectious Diseases news Respiratory

Blood Transcriptomic Signatures as Predictors of Poor Outcomes in Drug-Susceptible Pulmonary Tuberculosis: Insights from a Brazilian Cohort

By MedXY 09/17/2026

Host blood transcriptomic signatures effectively monitor treatment response and predict recurrence and mortality in drug-susceptible pulmonary tuberculosis, meeting WHO benchmarks and enabling personalized therapy strategies.

Clinical Updates news Respiratory

Early Biologic Initiation in Severe Asthma: Enhancing Remission and Clinical Outcomes from Global Real-World Cohorts

By MedXY 09/16/2026

Earlier initiation of biologic therapies in severe asthma improves clinical remission rates, reduces exacerbations, preserves lung function, and decreases corticosteroid dependence, supporting a shift from reserving to preserving treatment paradigms.

Critical Care news Respiratory

Extracorporeal Membrane Oxygenation without Mechanical Ventilation in ARDS: Insights from an International Cohort Study

By MedXY 09/16/2026

This study evaluates ECMO as a standalone respiratory support in ARDS patients avoiding invasive mechanical ventilation, highlighting outcomes, strategy failures, and mortality implications.

Clinical Updates news Respiratory

From Mild-to-Moderate to Severe Asthma: Risk Factors and Patient Profiles from the NORDSTAR Cohort and Advances in Severe Asthma Management

By MedXY 09/16/2026

This review summarizes the progression risk from mild-to-moderate to severe asthma based on the NORDSTAR cohort and integrates emerging evidence on biologic therapies that improve severe asthma outcomes across diverse patient profiles.

Cardiology news Respiratory

Distinct Lipid Metabolic Profiles Unveil Pathophysiological Differences Between Postcapillary and Combined Pre- and Postcapillary Pulmonary Hypertension

By MedXY 09/14/2026

This study reveals unique fatty acid and oxylipin metabolic signatures that differentiate isolated postcapillary pulmonary hypertension from combined pre- and postcapillary PH, highlighting potential biomarkers and therapeutic targets.

Cardiology Clinical Updates news Pediatrics Respiratory

Rapid Immunoassay for Molecular Subphenotyping in Pediatric Acute Cardiorespiratory Failure: Clinical Implications and Future Directions

By MedXY 09/13/2026

Rapid immunoassay-based classifiers accurately identify hyper- and hypoinflammatory subphenotypes in critically ill children, preserving prognostic and predictive utility and enabling precision therapies in acute pediatric cardiorespiratory failure.

Clinical Updates news Respiratory

Astegolimab for Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Insights from the Pooled ALIENTO and ARNASA Trials

By MedXY 09/13/2026

Astegolimab, an anti-ST2 monoclonal antibody, significantly reduced moderate/severe exacerbations in COPD patients with frequent exacerbations in pooled ALIENTO and ARNASA analyses, showing promise for targeting the IL-33/ST2 pathway with good safety.

Allergy & Immunology news Respiratory

Tezepelumab Demonstrates Robust Efficacy and Safety Across Diverse Severe Asthma Phenotypes: Insights from the Phase 4 PASSAGE Study

By MedXY 09/12/2026

The PASSAGE phase 4 study reveals tezepelumab significantly reduces exacerbation rates and improves lung function and quality of life in a broad US severe asthma population, including underrepresented groups and varied phenotypes.

news Respiratory

Efficacy of Dupilumab in Reducing COPD Exacerbations, Emergency Department Visits, and Corticosteroid Use: Insights from a Pooled Phase 3 Analysis

By MedXY 09/12/2026

Dupilumab significantly reduces emergency visits, hospital admissions, and systemic corticosteroid use in COPD patients with type 2 inflammation, offering a promising therapeutic option to mitigate exacerbation-associated morbidity.